Inhibition of glucagon secretion or antagonism of glucagon receptors has become a potentially effective treatment strategy for T2DM patients (Lund et al., 2014)
Researchers are investigating the potential of these drugs further
These studies assessed the efficacy and safety of escalating weekly doses of tirzepatide from 5 mg to 15 mg over 12 weeks compared to placebo,188 and over 26 weeks compared to placebo or dulaglutide, selective GLP-1RAs.189 Subsequently, tirzepatide has been extensively investigated in the SURPASS program, a comprehensive development initiative targeting T2DM that is inadequately controlled by various glucose-lowering regimens, including lifestyle alone (SURPASS-1),190 metformin monotherapy (SURPASS-2),191 metformin with or without sodium-glucose co-transporter 2 inhibitors (SGLT2i) (SURPASS-3),192 combination therapy including metformin, SGLT2i, and sulfonylureas (SURPASS-4),193 insulin glargine with or without metformin (SURPASS-5),88 and insulin lispro with basal insulin (SURPASS-6).194 Across all SURPASS trials, tirzepatide demonstrated a dose-dependent reduction in HbA1c levels, which consistently exceeded the reductions observed with comparator treatments
Following the application of exenatide, other GLP-1 receptor (GLP-1R) activators were developed such as liraglutide (Lira)
HR, 0.88
By targeting the GLP-1 pathway through natural ingredients rather than pharmaceuticals, Nutrex offers consumers an alternative approach to appetite control and weight management without the needles or potential side effects of prescription options
